Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates

Abstract

Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are generally low, with few exceptions, regardless of the solid cancer type or drug regimen. We investigated CR rates reported in the literature for clinical trials using chemotherapy alone, across a wide range of tumour types and chemotherapeutic regimens, to determine an overall CR rate for late-stage cancers. A total of 141 reports were located using the PubMed database. A meta-analysis was performed of reported CR from 68 chemotherapy trials (total 2732 patients) using standard agents across late-stage solid cancers—a binomial model with random effects was adopted. Mean CR rates were compared for different cancer types, and for chemotherapeutic agents with different mechanisms of action, using a logistic regression. Our results showed that the CR rates for chemotherapy treatment of late-stage cancer were generally low at 7.4%, regardless of the cancer type or drug regimen used. We found no evidence that CR rates differed between different chemotherapy drug types, but amongst different cancer types small CR differences were evident, although none exceeded a mean CR rate of 11%. This remarkable concordance of CR rates regardless of cancer or therapy type remains currently unexplained, and motivates further investigation.

Chemotherapy-induced release of circulating-tumor cells into the bloodstream in collective migration units with cancer-associated fibroblasts in metastatic cancer patients

“…For this small cohort of patients, the CTC and CAF levels gradually increased despite treatment. Increasing CTC levels have been widely used as a clinical biomarker for disease progression and prognosis in metastatic cancer [27][28][29]. However, few studies have determined the correlation of CAF levels with disease progression in patients diagnosed with breast, prostate and colorectal cancer [11].…”

Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials

“…Since the 20thcentury, cancer therapy has been characterized by ups and downs that are not only due to the ineffectiveness of therapies and side effects, but also conditioned by hope and the fact that in many cases, there has been complete remission [ 1 ]. Chemotherapy was the first identified therapeutic approach that systemically delivered chemical agents into tumor tissue and destroyed the large mass, but did not eliminate the disease [ 2 ]. In addition to short-term improvement in survival, this treatment has some limitations, such as the high risk of toxicity for rapidly renewing cells, like skin and gastrointestinal cells, and blood stem cells [ 3 ].…”

Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update

“…For example, older patients tend to be more vulnerable to the detrimental effects that are exerted by chemotherapeutic drugs due to alterations in pharmacokinetics with advancing age, resulting in poorer drug clearance [ 41 ]. Likewise, low complete response rate to chemotherapy was also observed among patients with more advanced cancer [ 42 ]. Therefore, the optimal drug choice/dosage to be used in cancer treatment needs to be determined for each individual patient in order to ensure that the treatment would be safe and effective for every patient, and this remains to be one major challenge for oncologists and physicians.…”